Recherche
-
Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database
(Atherosclerosis. vol. 281, pp. 98-106, 2019)Article de revue -
Effectiveness and safety of 110 or 150 mg dabigatran vs. vitamin K antagonists in nonvalvular atrial fibrillation
(British Journal of Clinical Pharmacology. vol. 85, n° 2, pp. 432-441, 2019)Article de revue -
Risk of hospital admission for liver injury in users of NSAIDs and nonoverdose paracetamol: Preliminary results from the EPIHAM study
(Pharmacoepidemiology and drug safety. vol. 27, n° 11, pp. 1174-1181, 2018-11)Article de revue -
Comparative Effectiveness and Safety of Standard or Reduced Dose Dabigatran vs. Rivaroxaban in Nonvalvular Atrial Fibrillation
(Clinical Pharmacology and Therapeutics. vol. 105, n° 6, pp. 1439-1455, 2019)Article de revue -
Comparative effectiveness of direct oral anticoagulants versus low-molecular weight heparins for the prevention of venous thromboembolism after total hip or knee replacement: A nationwide database cohort study
(Pharmacological Research. vol. 141, pp. 201-207, 2019)Article de revue -
An observational cohort study of the use of five-grass-pollen extract sublingual immunotherapy during the 2015 pollen season in France
(Allergy, Asthma and Clinical Immunology. vol. 14, pp. 38, 2018-09-24)Article de revueLibre accès -
Effectiveness and Safety of Rivaroxaban 15 or 20 mg Versus Vitamin K Antagonists in Nonvalvular Atrial Fibrillation
(Stroke. vol. 50, n° 9, pp. 2469-2476, 2019)Article de revueLibre accès -
Treatment resistant depression incidence and prevalence using the French nationwide claims database
(Pharmacoepidemiology and Drug Safety. vol. 30, n° 2, pp. 169–177, 2021-02)Article de revue